Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is strategically enhancing its position in the regenerative medicine and aesthetics sector, supported by a robust intellectual property portfolio that includes a key patent expiring in 2039. The partnership with AbbVie has proven fruitful, generating $24 million in milestone payments towards a potential total of $50 million, which underscores the commercial viability of CollPlant's rhCollagen technology. Additionally, the implementation of cost optimization strategies indicates prudent financial management aimed at extending the company's operational runway while it prepares for human trials, further solidifying its growth prospects.

Bears say

CollPlant Biotechnologies Ltd faces significant challenges that negatively impact its financial outlook, notably its reliance on a limited product range and revenue streams, primarily from collaborations and specialized markets. Additionally, the company's dependence on innovative technologies such as 3D bioprinting and recombinant human collagen may not be sufficient to sustain profitability in the face of competitive pressures and market uncertainties. Furthermore, the financial reports suggest that while the company operates across several regions, the concentration of key revenue sources in specific markets could pose risks to its overall growth and stability.

CLGN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLGN has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.